Acute myeloid leukemia with CEBPA mutations [AMLSG cohort]: mononuclear cells
Summary:
Analysis of mononuclear cells from bone marrow of untreated AML patients with CCAAT/enhancer binding protein alpha double mutation (CEBPAdm) or single mutation (CEBPAsm). Favorable outcome is observed in AML patients with CEBPAdm. Results provide insight into molecular basis of AML classification.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Taskesen E, Bullinger L, Corbacioglu A, Sanders MA et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011 Feb 24;117(8):2469-75. PMID: 21177436
